Latest news with #Restylane
Time of India
3 days ago
- Health
- Time of India
Here's what went wrong with Uorfi Javed's filler dissolution; experts highlight what happens when a face enhancements is dissolved
Uorfi Javed, the social media sensation, on Sunday dropped a video showing her lip filler procedure, and the result of the treatment left the internet in shock. In the clip, the 'Traitor' winner's lips looked swollen, and her face was unrecognisable. However, Uorfi got her fillers dissolved after about 9 years, but does filler removal look this dramatic? Let's find out. Fillers have a huge fan base, and that's all because of their ability to contour and rejuvenate the face. But what happens when a person dissolves their fillers? Or what if, after the swelling has gone down, you should wait to take action? Experts regularly use hyaluronidase to dissolve hyaluronic acid (HA) fillers like Juvederm or Restylane. 'This enzyme breaks down HA by specifically targeting its molecular bonds, resulting in an immediate disintegration. The process begins right away; however, it may take hours or days before any discernible progress is made,' says Dr. Mahnaz Jahan Begum, an esteemed aesthetic expert, entrepreneur, and founder of Keradis, a board-certified super specialist, cosmetic plastic and hair transplant surgeon, and medical director of Aterm Clinics-Kolkata. Myths and facts decoded: What happens when a face filler is dissolved? As the filler dissolves, patients should expect to experience temporary swelling, redness, or mild unevenness before the skin gradually returns to its natural state. According to Dr. Begum, 'The majority of the filler is metabolised in 1-2 weeks, and most patients have an initial reduction in 24–48 hours. Subtle changes, however, may persist for as long as four weeks. After two weeks, a second session could be necessary to remove thicker or layered fillers completely. The final result is determined by the body's natural processes; thus, patience is essential.' Not all fillers can be reversed Only fillers based on HA react to hyaluronidase. 'Different methods are needed for substitutes like silicone or Sculptra. Mild swelling and transient indentation are frequent side effects that go away fast,' adds Dr. Begum. Although skin usually returns to its natural state, prolonged use of fillers may cause mild stretching. To guarantee safe and efficient treatment, always seek advice from a certified professional. How dangerous can face fillers be (are they fatal)? 'Face fillers are not deadly if a certified one is used and done by a professional trainer, and too much of everything is awful,' says Dr. Shilpi Behl, Aesthetic Expert & Trainer. Infections or allergic reactions could be faced by some individuals Filler migration is another negative effect if it happens! Wrong injection points can lead to vascular complications or even tissue necrosis. Gone are the days when people wanted those high cheeks and pouty lips. 'More subtle & natural' is what is in now. Maintenance is also necessary, as good fillers last a maximum of 1 year or so. Fillers can be dissolved instantly, but that particular facial area would take a few days to show the proper anatomy and shape. To stay updated on the stories that are going viral, follow Indiatimes Trending.
Elle
7 days ago
- Health
- Elle
‘Skin Longevity': Why You're Seeing This Beauty Buzzword Everywhere
Every item on this page was chosen by an ELLE editor. We may earn commission on some of the items you choose to buy. When I applied for my first beauty editor job, the listing didn't include, 'thinking every day about how you will slowly march towards death'—the cerebral answer that a 20-something actress once gave me when I asked how she thought about aging. Still, on my desk and in our magazine's beauty closet, there are hundreds of creams and serums focused on anti-aging. The labels promise to prevent, to reverse, to freeze—time, I suppose, and the evidence of it. But one recent day at Equinox, I saw a new phrase airbrushed onto the wall near the spa like an ancient mythic text: 'Skin Longevity.' The biggest beauty companies in the world are positioning skin longevity moisturizers and serums as the new frontier in wellness—beauty products to go along with your cold plunges and tonal linen sets. In 2023, Estée Lauder founded a Skin Longevity platform, complete with an advisory panel of 'pro-aging' dermatologists from top medical and research institutions. Its Re-Nutriv line even includes a complex made of sirtuins, which experts call the 'longevity gene.' Earlier this month in Paris, L'Oreal presented its Longevity Integrative Science initiative, announcing its new focus. WWD recently reported that facialist Pietro Simone is opening up a 'skin longevity playground' in the West Village. Charlotte Palermino, the founder of the skin care brand Dieux, says that on a recent trip to Seoul, South Korea—largely considered the epicenter of beauty innovation—she saw an entire beauty section devoted to skin longevity. Even on PubMed, an online database of scientific research papers, 'you see that the longevity term has gone up exponentially,' says Zakia Rahman M.D., a dermatologist at Stanford Medical School who studies at the school's Center on Longevity. In short, skin longevity is the movement towards lasting skin health. 'For us, it is synonymous,' says Charles Rosier, co-founder of the science-backed beauty brand Augustinus Bader. The company recently launched an AI-powered longevity metric tracking platform in partnership with Deepak Chopra called AB Chopra Epigenetics. 'We're talking about trying to keep skin cells as healthy as possible to prevent them from aging prematurely, [which happens] when you subject them to environmental stress,' explains Alan Widgerow, M.D., chief scientific officer at Galderma, the global dermatology company that owns Cetaphil and Restylane. Stanford's Rahman simplifies the concept for her patients as: 'Your skin looks better because it's working better. Longevity is the optimal functioning of your cells.' Many brands are rooting their formulations to a discovery made years ago by scientists studying cognitive decline and other age-related disorders. They found that the accumulation of non-functioning cells—referred to as senescent, or more colloquially as 'zombie cells'—leads to accelerated aging. But zombie cells can also cause wrinkles and the skin to look more dull, obviously of interest to the beauty industry. Skin longevity is not technically a synonym for anti-aging, in the same way that soft serve is not ice cream, an emoji is not an emoticon, and Meghan Markle's 'fruit spreads' are not jam. The concepts are related, but different and nuanced. As an exercise, I asked experts what treatments or formulations they considered to be skin longevity, versus traditional anti-aging. Sunscreen and anti-oxidants (like vitamin C) are considered protective in nature, so they fall under skin longevity. Anything regenerative or that stimulates collagen, including retinol, peptides, polynucleotides, PDRN (in the form of salmon sperm), or even certain fillers like Radiesse or Sculptra would be classified as skin longevity. (Conveniently, a lot of what already exists in the beauty industry can be classified as skin longevity.) The discussion got a little trickier when it came to Botox. For instance, Rosier says a neurotoxin injection doesn't qualify as skin longevity: 'According to us at Augustinus, not so much, because it weakens the muscles. Our vision of skin longevity is more about empowering elasticity in the skin.' But according to Rahman, 'It absolutely does.' She points to different applications of Botox, including when it is injected into scars to help heal tissues. 'Botox affects the quality of the skin' at a base level, she reasons. In those areas where skin is less elastic or atrophic, you can have a depression and thinning of the skin, which Botox can help. Does getting a facelift at 40 count as skin longevity? Don't be so quick to scoff. It depends on how you think about it. 'When people think about their goals, it includes preparation for how you will age in the future. How do you want to look and how do you want to age?' says Shereene Idriss, M.D., a dermatologist in New York City. To some, this new thinking feels more positive and proactive. Anti-aging is futile. 'You're set up to fail,' Idriss says. 'You're never going to fight the aging process. It implies that something is wrong with you, that you're fighting something.' In contrast, Palermino says, 'Skin longevity feels truthful because you are actually improving the longevity of your skin. You're making it stronger for longer, just like working out is good for you.' It's also gender neutral, speaking the language of Silicon Valley biohackers and Instagram wellness influencers alike. A tech bro with a 'skin care protocol' is not into beauty, but he is into 'skin longevity.' The wellness industry is now three times the size of the pharmaceutical industry, and driving the skin longevity trend. 'Men don't want to be seen as feminine. Skin longevity must be a capitalist dream, because it makes beauty palatable to women and inspirational to men,' theorizes Palermino. Just as wellness can easily disguise diet culture, and emphasize thinness, pseudoscience, and unrealistic expectations, skin longevity could just further exacerbate our culture's obsession with youth. It could become anti-aging, just with a cuter outfit. 'There are excellent things with the wellness industry, but it can go sideways very quickly. With beauty, I could see the same thing where skin longevity is really just a code word for looking young forever. That's where I would challenge the industry to not go,' Palermino says. Some people may still roll their eyes at the term. Rahman was speaking to a retired colleague of hers at Stanford who extensively studied epigenetics and big data. When talking to him about the school's skin longevity program, his reaction was, Of course, people care about how they look. Rahman told him: 'I don't want you to think of it as vanity. I want you to think of it as vitality.' She calls it a light bulb moment. 'When people understand it that way, they embrace it the same way that they do optimizing their muscle, cardiovascular, or brain function.' This 'glass half full' approach (as Idriss calls it) has already appeared in some beauty marketing. Shiseido's new Ultimune Power Infusing Serum has tempered expectations, says Salina Urben, senior manager of U.S. education and training for the brand. 'We're not going to say it carves 20 years off your skin, but there's something about truly healthy skin that's beautiful and radiates.' Ideally, adds Palermino, skin longevity could become a healthier way of looking at getting older. 'We need to make aging the beauty standard. It's okay to age. It's a beautiful thing to age. How you want to age is what differs.'
Yahoo
17-07-2025
- Health
- Yahoo
Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss
Final data from a first-of-its-kind clinical trial confirm that the combination of Sculptra® and Restylane® Lyft™ or Contour™* delivers sustained improvement in facial aesthetic appearance for patients experiencing facial volume loss due to medication-driven weight loss1 Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months1 Galderma continues to lead the response to addressing the aesthetic concerns of patients experiencing medication-driven weight loss, leveraging its deep dermatological expertise and working closely with healthcare professionals to meet evolving patient needs ZUG, Switzerland, July 17, 2025--(BUSINESS WIRE)--Galderma has revealed positive final data from a phase IV first-of-its-kind trial exploring the benefits of Restylane Lyft or Contour in combination with Sculptra to address the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss.1 These data reinforce that this treatment regimen can effectively improve facial aesthetic appearance with high patient satisfaction over nine months.1 Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude.2-4 Patients may experience facial changes such as dry, dull or sagging skin, a gaunt or hollowed-out facial appearance, or other unwelcome alterations to facial structure and balance.3,4 As the pure-play dermatology category leader, Galderma is spearheading efforts to identify and address the most predominant aesthetic concerns of patients along their weight loss journey. "At Galderma, we are leading the charge in redefining aesthetic care for patients impacted by medication-driven weight loss. Our commitment is clear: to empower individuals to reclaim their confidence through cutting-edge, data-driven innovation and strategic collaboration with the world's foremost experts, and these latest study results reinforce this mission." FLEMMING ØRNSKOV, M.D., MPHCHIEF EXECUTIVE OFFICERGALDERMA In the phase IV clinical study conducted in the U.S., Galderma investigated the aesthetic outcomes and appearance, and patient satisfaction of Restylane Lyft or Contour in combination with Sculptra for cheek or jawline augmentation and correction of contour deficiencies in patients experiencing facial volume loss associated with medication-driven weight loss.1 The trial used the SHAPE Up Holistic Individualized Treatment (HIT™) – an individualized treatment approach which enables injectors to leverage their expertise with Galderma's Sculptra and its Restylane portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction. Patients were treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8.1 Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months. In the extension study, follow-up visits took place at Weeks 32 and 44 for those who received the third Sculptra treatment and at Weeks 28 and 40 for those who did not, corresponding to nine months after their first Sculptra treatment.1 Results at nine months demonstrated that the combination of Sculptra and Restylane Lyft or Contour effectively improved the aesthetic appearance of patients experiencing facial volume loss associated with medication-driven weight loss, further supporting the benefits of the SHAPE Up HIT:1 The combined Sculptra and Restylane Lyft or Contour regimen demonstrated skin quality improvements, with Restylane improving skin hydration and Sculptra significantly improving skin radiance through to Month 91 Subject satisfaction – which was reported by the majority of patients as early as Week 4 – was maintained through to Month 9:1 85.7% of patients said their face looked less gaunt/sunken1 88.6% said they "loved" how the treatment maintained their facial structure1 88.6% of patients said they "loved" the regenerative effects of Sculptra treatment1 88.6% felt they looked better than before the injection regimen1 91.4% said they would recommend the injection regimen to others after weight loss and to those with loose, sagging facial skin1 Safety was in line with previous pivotal trial data for Sculptra, Restylane Lyft and Contour, with no treatment-related adverse events reports.1 "The improvements we observed with Sculptra and Restylane at nine months are hugely encouraging and represent a meaningful step forward in addressing the most predominant aesthetic concerns of patients along their weight loss journey. It was exciting to see the glow we've clinically observed in the past with Sculptra now validated through innovative bioinstrumentation tools in this study. For physicians and patients who are navigating the visible effects of medication-driven weight loss, this study delivers real, evidence-based solutions that can make a tangible difference to how individuals look and feel." Z. PAUL LORENC, TRIAL INVESTIGATORNEW YORK, UNITED STATES "These results really reinforce the role of aesthetic treatments, like Sculptra and Restylane, in supporting patients through their weight loss transformations, showing they can deliver visible improvements in skin quality while also significantly enhancing patient satisfaction and emotional wellbeing. The findings empower clinicians with data-backed tools to holistically address the nuanced aesthetic needs that arise with medication-driven weight loss, marking a pivotal moment where science meets patient-centered care." MICHAEL SOMENEK, TRIAL INVESTIGATORWASHINGTON DC, UNITED STATES Galderma is spearheading multiple additional initiatives to identify and address the most predominant aesthetic concerns of patients who have experienced medication-driven weight loss through data-driven, innovative approaches in close collaboration with leading healthcare practitioners, as outlined in the company's recent report.5 Galderma has supported pioneering research in the field, including the first recently published international consensus-based guidelines that provide a practical framework for practitioners to address the aesthetic needs of medication-driven weight loss patients, as well as research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient journey.6 *Restylane Contour is known as Restylane® Volyme™ in countries outside of the U.S. About the studyThis phase IV trial was a multi-center, open-label study to evaluate the synergistic effects of Restylane Lyft or Contour in combination with Sculptra for cheek augmentation and correction of contour deficiencies, in patients experiencing facial volume loss following treatment with one of four brands of glucagon-like peptide-1 (GLP-1) receptor agonists.1 Conducted in the U.S., the trial took place across two sites, and used the SHAPE Up Holistic Individualized Treatment (HIT) as a treatment methodology, with patients treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8.1 About GaldermaGalderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: References Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label study to evaluate the synergistic effects of biostimulator and dermal fillers for cheek augmentation and correction of contour deficiencies: Nine-month topline results. Mansour MR, et al. The rise of "Ozempic Face": Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. JPRAS. 2024;96:225-227. doi: 10.1016/ Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. JPRAS. 2023;81:97-98. doi: 10.1016/ Humphrey CD and Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721. doi: 10.1055/a-2148-6321 Galderma. Balancing The Scales: Advancing Aesthetics In The Era Of Medication-driven Weight Loss Transformations. July 2025. Available online Nikolis A, et al. Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study. JCD. 2025;24: e70094. View source version on Contacts Christian Marcoux, Communications +41 76 315 26 50 Richard HarbinsonCorporate Communications +41 76 210 60 62 Céline BuguetFranchises and R&D Communications +41 76 249 90 87 Emil IvanovHead of Strategy, Investor Relations, and +41 21 642 78 12 Jessica CohenInvestor Relations and Strategy +41 21 642 76 43
Business Wire
17-07-2025
- Health
- Business Wire
Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss
ZUG, Switzerland--(BUSINESS WIRE)--Galderma has revealed positive final data from a phase IV first-of-its-kind trial exploring the benefits of Restylane Lyft or Contour in combination with Sculptra to address the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss. 1 These data reinforce that this treatment regimen can effectively improve facial aesthetic appearance with high patient satisfaction over nine months. 1 Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude. 2-4 Patients may experience facial changes such as dry, dull or sagging skin, a gaunt or hollowed-out facial appearance, or other unwelcome alterations to facial structure and balance. 3,4 As the pure-play dermatology category leader, Galderma is spearheading efforts to identify and address the most predominant aesthetic concerns of patients along their weight loss journey. "At Galderma, we are leading the charge in redefining aesthetic care for patients impacted by medication-driven weight loss. Our commitment is clear: to empower individuals to reclaim their confidence through cutting-edge, data-driven innovation and strategic collaboration with the world's foremost experts, and these latest study results reinforce this mission." FLEMMING ØRNSKOV, M.D., MPH CHIEF EXECUTIVE OFFICER GALDERMA In the phase IV clinical study conducted in the U.S., Galderma investigated the aesthetic outcomes and appearance, and patient satisfaction of Restylane Lyft or Contour in combination with Sculptra for cheek or jawline augmentation and correction of contour deficiencies in patients experiencing facial volume loss associated with medication-driven weight loss. 1 The trial used the SHAPE Up Holistic Individualized Treatment (HIT™) – an individualized treatment approach which enables injectors to leverage their expertise with Galderma's Sculptra and its Restylane portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction. Patients were treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8. 1 Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months. In the extension study, follow-up visits took place at Weeks 32 and 44 for those who received the third Sculptra treatment and at Weeks 28 and 40 for those who did not, corresponding to nine months after their first Sculptra treatment. 1 Results at nine months demonstrated that the combination of Sculptra and Restylane Lyft or Contour effectively improved the aesthetic appearance of patients experiencing facial volume loss associated with medication-driven weight loss, further supporting the benefits of the SHAPE Up HIT: 1 The combined Sculptra and Restylane Lyft or Contour regimen demonstrated skin quality improvements, with Restylane improving skin hydration and Sculptra significantly improving skin radiance through to Month 9 1 Subject satisfaction – which was reported by the majority of patients as early as Week 4 – was maintained through to Month 9: 1 85.7% of patients said their face looked less gaunt/sunken 1 88.6% said they 'loved' how the treatment maintained their facial structure 1 88.6% of patients said they 'loved' the regenerative effects of Sculptra treatment 1 88.6% felt they looked better than before the injection regimen 1 91.4% said they would recommend the injection regimen to others after weight loss and to those with loose, sagging facial skin 1 Safety was in line with previous pivotal trial data for Sculptra, Restylane Lyft and Contour, with no treatment-related adverse events reports. 1 "The improvements we observed with Sculptra and Restylane at nine months are hugely encouraging and represent a meaningful step forward in addressing the most predominant aesthetic concerns of patients along their weight loss journey. It was exciting to see the glow we've clinically observed in the past with Sculptra now validated through innovative bioinstrumentation tools in this study. For physicians and patients who are navigating the visible effects of medication-driven weight loss, this study delivers real, evidence-based solutions that can make a tangible difference to how individuals look and feel." Z. PAUL LORENC, M.D. CLINICAL TRIAL INVESTIGATOR NEW YORK, UNITED STATES "These results really reinforce the role of aesthetic treatments, like Sculptra and Restylane, in supporting patients through their weight loss transformations, showing they can deliver visible improvements in skin quality while also significantly enhancing patient satisfaction and emotional wellbeing. The findings empower clinicians with data-backed tools to holistically address the nuanced aesthetic needs that arise with medication-driven weight loss, marking a pivotal moment where science meets patient-centered care." MICHAEL SOMENEK, M.D. CLINICAL TRIAL INVESTIGATOR WASHINGTON DC, UNITED STATES Galderma is spearheading multiple additional initiatives to identify and address the most predominant aesthetic concerns of patients who have experienced medication-driven weight loss through data-driven, innovative approaches in close collaboration with leading healthcare practitioners, as outlined in the company's recent report. 5 Galderma has supported pioneering research in the field, including the first recently published international consensus-based guidelines that provide a practical framework for practitioners to address the aesthetic needs of medication-driven weight loss patients, as well as research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient journey. 6 * Restylane Contour is known as Restylane ® Volyme™ in countries outside of the U.S. About the study This phase IV trial was a multi-center, open-label study to evaluate the synergistic effects of Restylane Lyft or Contour in combination with Sculptra for cheek augmentation and correction of contour deficiencies, in patients experiencing facial volume loss following treatment with one of four brands of glucagon-like peptide-1 (GLP-1) receptor agonists. 1 Conducted in the U.S., the trial took place across two sites, and used the SHAPE Up Holistic Individualized Treatment (HIT) as a treatment methodology, with patients treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8. 1 About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: References Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label study to evaluate the synergistic effects of biostimulator and dermal fillers for cheek augmentation and correction of contour deficiencies: Nine-month topline results. Mansour MR, et al. The rise of 'Ozempic Face': Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. JPRAS. 2024;96:225-227. doi: 10.1016/ Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. JPRAS. 2023;81:97-98. doi: 10.1016/ Humphrey CD and Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721. doi: 10.1055/a-2148-6321 Galderma. Balancing The Scales: Advancing Aesthetics In The Era Of Medication-driven Weight Loss Transformations. July 2025. Available online Nikolis A, et al. Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study. JCD
National Post
17-07-2025
- Health
- National Post
Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss
Article content Sorry, your browser doesn't support embedded videos. Article content Final data from a first-of-its-kind clinical trial confirm that the combination of Sculptra ® and Restylane ® Lyft™ or Contour™* delivers sustained improvement in facial aesthetic appearance for patients experiencing facial volume loss due to medication-driven weight loss 1 Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months 1 Galderma continues to lead the response to addressing the aesthetic concerns of patients experiencing medication-driven weight loss, leveraging its deep dermatological expertise and working closely with healthcare professionals to meet evolving patient needs Article content Article content ZUG, Switzerland — Galderma has revealed positive final data from a phase IV first-of-its-kind trial exploring the benefits of Restylane Lyft or Contour in combination with Sculptra to address the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss. 1 These data reinforce that this treatment regimen can effectively improve facial aesthetic appearance with high patient satisfaction over nine months. 1 Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude. 2-4 Patients may experience facial changes such as dry, dull or sagging skin, a gaunt or hollowed-out facial appearance, or other unwelcome alterations to facial structure and balance. 3,4 As the pure-play dermatology category leader, Galderma is spearheading efforts to identify and address the most predominant aesthetic concerns of patients along their weight loss journey. Article content 'At Galderma, we are leading the charge in redefining aesthetic care for patients impacted by medication-driven weight loss. Our commitment is clear: to empower individuals to reclaim their confidence through cutting-edge, data-driven innovation and strategic collaboration with the world's foremost experts, and these latest study results reinforce this mission.' Article content GALDERMA Article content In the phase IV clinical study conducted in the U.S., Galderma investigated the aesthetic outcomes and appearance, and patient satisfaction of Restylane Lyft or Contour in combination with Sculptra for cheek or jawline augmentation and correction of contour deficiencies in patients experiencing facial volume loss associated with medication-driven weight loss. 1 The trial used the SHAPE Up Holistic Individualized Treatment (HIT™) – an individualized treatment approach which enables injectors to leverage their expertise with Galderma's Sculptra and its Restylane portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction. Article content Patients were treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8. 1 Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months. In the extension study, follow-up visits took place at Weeks 32 and 44 for those who received the third Sculptra treatment and at Weeks 28 and 40 for those who did not, corresponding to nine months after their first Sculptra treatment. 1 Results at nine months demonstrated that the combination of Sculptra and Restylane Lyft or Contour effectively improved the aesthetic appearance of patients experiencing facial volume loss associated with medication-driven weight loss, further supporting the benefits of the SHAPE Up HIT: 1 The combined Sculptra and Restylane Lyft or Contour regimen demonstrated skin quality improvements, with Restylane improving skin hydration and Sculptra significantly improving skin radiance through to Month 9 1 Subject satisfaction – which was reported by the majority of patients as early as Week 4 – was maintained through to Month 9: 1 85.7% of patients said their face looked less gaunt/sunken 1 88.6% said they 'loved' how the treatment maintained their facial structure 1 88.6% of patients said they 'loved' the regenerative effects of Sculptra treatment 1 88.6% felt they looked better than before the injection regimen 1 91.4% said they would recommend the injection regimen to others after weight loss and to those with loose, sagging facial skin 1 Safety was in line with previous pivotal trial data for Sculptra, Restylane Lyft and Contour, with no treatment-related adverse events reports. 1 'The improvements we observed with Sculptra and Restylane at nine months are hugely encouraging and represent a meaningful step forward in addressing the most predominant aesthetic concerns of patients along their weight loss journey. It was exciting to see the glow we've clinically observed in the past with Sculptra now validated through innovative bioinstrumentation tools in this study. For physicians and patients who are navigating the visible effects of medication-driven weight loss, this study delivers real, evidence-based solutions that can make a tangible difference to how individuals look and feel.' Article content 'These results really reinforce the role of aesthetic treatments, like Sculptra and Restylane, in supporting patients through their weight loss transformations, showing they can deliver visible improvements in skin quality while also significantly enhancing patient satisfaction and emotional wellbeing. The findings empower clinicians with data-backed tools to holistically address the nuanced aesthetic needs that arise with medication-driven weight loss, marking a pivotal moment where science meets patient-centered care.' Article content MICHAEL SOMENEK, M.D. Article content WASHINGTON DC, UNITED STATES Article content Galderma is spearheading multiple additional initiatives to identify and address the most predominant aesthetic concerns of patients who have experienced medication-driven weight loss through data-driven, innovative approaches in close collaboration with leading healthcare practitioners, as outlined in the company's recent report. 5 Galderma has supported pioneering research in the field, including the first recently published international consensus-based guidelines that provide a practical framework for practitioners to address the aesthetic needs of medication-driven weight loss patients, as well as research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient journey. 6 * Restylane Contour is known as Restylane ® Volyme™ in countries outside of the U.S. Article content About the study Article content This phase IV trial was a multi-center, open-label study to evaluate the synergistic effects of Restylane Lyft or Contour in combination with Sculptra for cheek augmentation and correction of contour deficiencies, in patients experiencing facial volume loss following treatment with one of four brands of glucagon-like peptide-1 (GLP-1) receptor agonists. Article content 1 Article content Conducted in the U.S., the trial took place across two sites, and used the SHAPE Up Holistic Individualized Treatment (HIT) as a treatment methodology, with patients treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8. Article content 1 Article content About Galderma Article content Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: Article content Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label study to evaluate the synergistic effects of biostimulator and dermal fillers for cheek augmentation and correction of contour deficiencies: Nine-month topline results. Mansour MR, et al. The rise of 'Ozempic Face': Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. JPRAS. 2024;96:225-227. doi: 10.1016/ Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. JPRAS. 2023;81:97-98. doi: 10.1016/ Humphrey CD and Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721. doi: 10.1055/a-2148-6321 Galderma. Balancing The Scales: Advancing Aesthetics In The Era Of Medication-driven Weight Loss Transformations. July 2025. Available online Nikolis A, et al. Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study. JCD. 2025;24: e70094. Article content Article content Article content Article content Article content Contacts Article content Christian Marcoux, Chief Communications Officer +41 76 315 26 50 Article content Richard Harbinson Corporate Communications Director +41 76 210 60 62 Article content Céline Buguet Franchises and R&D Communications Director +41 76 249 90 87 Article content Emil Ivanov Head of Strategy, Investor Relations, and ESG +41 21 642 78 12 Article content Article content Article content
